Cefpodoxime 200mg + Clavulanic Acid 125mg
Adult-strength cefpodoxime-clavulanate — Cefpodoxime 200mg (PBP binding, third-generation gram-positive/gram-negative coverage including MSSA) + Clavulanic Acid 125mg (beta-lactamase inhibitor protecting against ESBL and resistant beta-lactamase-producing organisms). The adult 200/125mg combination delivers the maximum oral cefpodoxime dose with full beta-lactamase protection — covering ESBL-producing E. coli, Klebsiella, resistant H. influenzae, M. catarrhalis, and MSSA simultaneously.
Adult moderate-to-severe infections with suspected resistant organisms: complicated UTIs and pyelonephritis with ESBL-producing gram-negatives, severe community-acquired pneumonia, recurrent sinusitis and otitis media unresponsive to standard cephalosporins, complicated skin infections, and gynaecological infections requiring broad-spectrum beta-lactamase-protected coverage.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
The 200/125mg adult cefpodoxime-clavulanate represents the premium end of oral beta-lactamase-protected cephalosporin prescribing — combining the highest adult cefpodoxime dose with clavulanate protection for the most resistant community infections. For physicians managing ESBL UTIs and treatment-failure respiratory infections without hospitalisation, PODROCK™ CV Adult provides the most pharmacologically robust oral option within the Seclis Labs portfolio.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.